AngioDynamics cuts FY24 EPS view to (42c) to (35c) from (34c) to (28c)

Consensus (32c). Cuts FY24 revenue view to $320M-$325M from $328M-$333M, consensus $329.1M. Cuts FY24 gross margin view to 49%-51% from 50%-52%. The company states: “The Company now expects its fiscal year 2024 net sales to be in the range of $320 to $325 million, accounting for the softer Thrombectomy sales during the fiscal second quarter, which it now expects will continue throughout the back half of the year, as well as certain SKU rationalization and other impacts associated with the manufacturing restructuring.”